GlassScriptPhysician profile
Penny L Burcham
NPI 1609967520
$22,042.33
in general payments reported to CMS, 2019-2025
58 companies · $4,733 in 2025
The $4,733 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,798 · 2022: $4,214 · 2023: $4,382 · 2024: $4,916 · 2025: $4,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,915.87 |
| Education | $114.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,671.62 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,329.15 | 2021-2025 | |
| Pfizer INC. | $1,287.35 | 2021-2025 | |
| Amgen INC. | $1,208.26 | 2021-2025 | Uplizna, Aimovig |
| Jazz Pharmaceuticals INC. | $1,187.95 | 2021-2025 | |
| Ucb, INC. | $1,032.45 | 2021-2025 | Nayzilam, Briviact, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $955.70 | 2021-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $905.50 | 2021-2025 | Emgality, Kisunla, Reyvow |
| Biogen, INC. | $900.64 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Sk Life Science, INC. | $789.59 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $776.43 | 2021-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $606.37 | 2021-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $544.08 | 2021-2025 | Zeposia |
| Emd Serono, INC. | $539.94 | 2021-2025 | Mavenclad |
| Lundbeck LLC | $513.21 | 2021-2025 | Vyepti, Rexulti |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $470.95 | 2022-2025 | Wakix |
| Genentech USA, INC. | $469.08 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Inspire Medical Systems, INC. | $420.27 | 2024-2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $419.97 | 2022 | |
| Eisai INC. | $419.33 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $401.59 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amneal Pharmaceuticals LLC | $394.08 | 2021-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Argenx US, INC. | $344.42 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Tanabe Pharma America, INC. | $322.32 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $270.06 | 2021 | |
| Janssen Pharmaceuticals, INC | $267.57 | 2021-2023 | Xarelto |
| Neurelis, INC. | $251.18 | 2022-2025 | Valtoco |
| Genzyme Corporation | $245.97 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $202.82 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $198.39 | 2023-2025 | Nuedexta, Rexulti |
| Merz Pharmaceuticals, LLC | $185.33 | 2022-2025 | Xeomin, Ampyra, Inbrija |
| Catalyst Pharmaceuticals, INC. | $155.23 | 2023-2025 | Firdapse, Fycompa |
| Tg Therapeutics, INC. | $122.63 | 2023-2025 | |
| Springworks Therapeutics, INC. | $108.25 | 2025 | Gomekli |
| Ani Pharmaceuticals, INC. | $94.25 | 2023-2025 | Purified Cortrophin Gel |
| Acorda Therapeutics, INC | $90.96 | 2023-2024 | Inbrija, Ampyra |
| Boston Scientific Corporation | $81.95 | 2023-2024 | Patient Trial Kit |
| Vanda Pharmaceuticals INC. | $79.69 | 2024-2025 | Ponvory |
| Corium, LLC | $79.53 | 2022-2023 | Adlarity |
| Kyowa Kirin, INC. | $77.54 | 2021 | |
| Csl Behring | $64.73 | 2023-2025 | Hizentra |
| Supernus Pharmaceuticals, INC. | $57.58 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $53.65 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $52.37 | 2022 | |
| Averitas Pharma INC. | $47.87 | 2023-2024 | Qutenza |
| Scilex Pharmaceuticals INC. | $42.48 | 2025 | |
| Grt US Holding, INC. | $40.97 | 2021-2022 | |
| Nevro Corp. | $39.79 | 2023 | Senza |
| Alnylam Pharmaceuticals INC. | $38.63 | 2023 | Onpattro |
| Fisher & Paykel Healthcare INC | $33.22 | 2023 | Fisher & Paykel Healthcare |
| Horizon Therapeutics Plc | $30.34 | 2021 | |
| Sumitomo Pharma America, INC. | $24.98 | 2024 | Aptiom |
| Avion Pharmaceuticals | $19.13 | 2022 | |
| Ge Healthcare | $17.66 | 2023 | |
| Janssen Biotech, INC. | $16.02 | 2025 | |
| Almatica Pharma LLC | $15.31 | 2021 | |
| Axsome Therapeutics, INC. | $14.80 | 2025 | Symbravo |
| Allergan, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penny Burcham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.